Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Immuneering Corp Cl A (IMRX)

Immuneering Corp Cl A (IMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,404
  • Shares Outstanding, K 29,653
  • Annual Sales, $ 0 K
  • Annual Income, $ -53,470 K
  • 60-Month Beta -0.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.53
Trade IMRX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.50
  • Number of Estimates 4
  • High Estimate -0.47
  • Low Estimate -0.54
  • Prior Year -0.43
  • Growth Rate Est. (year over year) -16.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3000 +10.00%
on 06/10/24
2.0100 -28.86%
on 06/11/24
-0.1100 (-7.14%)
since 05/21/24
3-Month
1.3000 +10.00%
on 06/10/24
3.1500 -54.60%
on 04/01/24
-1.3000 (-47.62%)
since 03/21/24
52-Week
1.3000 +10.00%
on 06/10/24
11.8100 -87.89%
on 06/22/23
-9.7300 (-87.19%)
since 06/21/23

Most Recent Stories

More News
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments

USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough...

ONCY : 1.0100 (+1.45%)
ONC.TO : 1.37 (+0.74%)
RHHBY : 35.5900 (+1.05%)
MRUS : 54.84 (+1.67%)
MGNX : 4.37 (+6.07%)
IMRX : 1.4300 (+1.42%)
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth

EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END

ONCY : 1.0100 (+1.45%)
ONC.TO : 1.37 (+0.74%)
BLRX : 0.5900 (unch)
IMRX : 1.4300 (+1.42%)
CADL : 6.04 (+1.00%)
Why Shares of Immuneering Jumped This Week

Immuneering is ready to share information regarding its lead therapy.

IMRX : 1.4300 (+1.42%)
Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer

Pyramid Biosciences, Inc., a Boston-based, clinical-stage, biotechnology company focused on developing new and highly differentiated precision therapies for cancer, today announced the expansion of its...

IMRX : 1.4300 (+1.42%)
Immuneering Announces Participation in William Blair Biotech Focus Conference 2022

CAMBRIDGE, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational...

IMRX : 1.4300 (+1.42%)
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical data package now includes animal studies...

IMRX : 1.4300 (+1.42%)
Immuneering Announces Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) --  Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational...

IMRX : 1.4300 (+1.42%)
Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights

IND filing for IMM-1-104 expected in Q3 2022; Enrollment of the first patient expected in Q4 2022  IND filing for IMM-6-415, designed to sensitize...

IMRX : 1.4300 (+1.42%)
Immuneering Announces Participation in Citi’s Biopharma VIRTUAL Co-Panel Day

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics...

IMRX : 1.4300 (+1.42%)
Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational...

IMRX : 1.4300 (+1.42%)

Business Summary

Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.5383
2nd Resistance Point 1.4967
1st Resistance Point 1.4633
Last Price 1.4300
1st Support Level 1.3883
2nd Support Level 1.3467
3rd Support Level 1.3133

See More

52-Week High 11.8100
Fibonacci 61.8% 7.7952
Fibonacci 50% 6.5550
Fibonacci 38.2% 5.3148
Last Price 1.4300
52-Week Low 1.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar